Immune Thrombocytopenic Purpura – Landscape & Forecast – Disease Landscape & Forecast
Immune thrombocytopenic purpura (ITP) is an autoimmune disease resulting in a low platelet count. Treatment of ITP involves the use of immunomodulators and corticosteroids as well as multiple therapies specifically approved for ITP. Thrombopoietin receptor agonists (TPO–RAs)—orally administered eltrombopag (Novartis’s Promacta / Revolade) and avatrombopag (Sobi’s Doptelet) and subcutaneously administered romiplostim (Amgen’s Nplate)—are key treatments for ITP. Rigel Pharmaceuticals / Grifols’ oral Tavalisse / Tavlesse (fostamatinib), a spleen tyrosine kinase inhibitor, is an option for treatment-refractory or unresponsive chronic ITP. Despite the availability of multiple therapies for ITP, effective treatments are needed for patients who are treatment-refractory or unresponsive to current therapies. Drugs that do not require chronic administration are also needed. Thus, ample commercial opportunity remains for pharmacotherapies with novel mechanisms of action as well as those with curative potential.
Questions answered
- What size are the ITP diagnosed prevalent populations (newly diagnosed, persistent, and chronic primary ITP) in the United States and EU5, and how will these populations change through 2032?
- How have the TPO–RAs and Tavalisse / Tavlesse been incorporated into the ITP treatment algorithm, and what is their commercial potential through 2032?
- What factors are driving and constraining market growth? Which new agents and classes of agents will emerge during the forecast period, and what impact will they have on the overall market?
Scope
- Geography: United States and EU5
- Primary research: Six country-specific interviews with thought-leading hematologists; supported by survey data collected for this study
- Epidemiology: Diagnosed incidence of ITP by country, diagnosed drug-treated prevalence of ITP by country, diagnosed prevalence of ITP by disease phase by country
- Forecast: Drug-level sales and patient share of key ITP therapies in 2022 and 2032
- Emerging therapies: Phase 3: 3 drugs; Phase 2: 3 drugs
Product description
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Niche & Rare Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Immune Thrombocytopenic Purpura - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Commercial Outlook
- Forecast
- Etiology and Pathophysiology
- Disease overview
- Etiology
- Pathophysiology
- Symptoms and complications
- Association between thrombocytopenia and bleeding
- Key differences between acute and chronic immune thrombocytopenic purpura
- Key differences between newly diagnosed, persistent, and chronic immune thrombocytopenic purpura
- Expert insight on differences between pathophysiology of persistent / chronic and newly diagnosed immune thrombocytopenic purpura
- Key pathways and drug targets
- Epidemiology
- Current Treatment
- Key findings
- Diagnosis
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for immune thrombocytopenic purpura
- Current treatments used for immune thrombocytopenic purpura
- Glucocorticoids
- Immunoglobulins
- Thrombopoietin-receptor agonists
- B-cell modulators
- Immunosuppressants and other agents
- Splenectomy
- Splenic tyrosine kinase inhibitors
- Medical practice
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for immune thrombocytopenic purpura
- Estimated launch dates of key emerging therapies for the treatment of immune thrombocytopenic purpura
- Spleen tyrosine kinase inhibitors
- Neonatal Fc receptor blockers
- Bruton's tyrosine kinase inhibitors
- Anti-CD38 MAbs
- B-cell activating factor receptor inhibitors
- Early-phase pipeline analysis
- Key discontinuations and failures in immune thrombocytopenic purpura
- Patient registries
- Orphan Drug designation
- Key findings
- Access & Reimbursement Overview
- Methodology
- Bottom-up forecasting overview
- Bottom-up forecast assumptions
- General sources of data
- Drug-treatment rate assumptions in immune thrombocytopenic purpura
- Patient-share assumptions in immune thrombocytopenic purpura
- General statements about pricing
- Sources for drug prices
- 2022 exchange rates
- Price per treated day: 2022
- Price per treated day: 2032
- Dosing, days of therapy, and compliance
- Generic erosion
- Generic erosion assumptions
- Out-year forecasting
- Emerging therapy prices
- Primary market research
- Appendix
Naomi López Caraballo, Ph.D., Healthcare Research & Data Analyst, Infectious, Niche, and Rare Diseases. Dr. López Caraballo is a healthcare research and data analyst for the rare disorders therapy market. She holds a Ph.D. in neuroscience and physiology from the New York University School of Medicine and a B.S. in industrial biotechnology from the University of Puerto Rico in Mayaguez.
Divya Grover, Associate Healthcare Research & Data Analyst, Infectious, Niche, and Rare Diseases. Prior to joining Clarivate, Ms. Grover was a senior research analyst at Olympus Research Global. She also worked as a senior associate at DelveInsight Business Research and a research associate at Unimrkt Health. She holds a bachelor of technology degree in biochemical technology from the University School of Chemical Technology (GGSIPU) in Delhi.
Navya Vardhan, M.Sc., Epidemiologist, Epidemiology. She obtained her M.Sc. in biostatistics and demography from the International Institute for Population Sciences in Mumbai. She also holds a B.Sc. in mathematics.